BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...Ltd. $95.0 Northwest Biotherapeutics Inc. (OTCQB:NWBO) $95.0 Mission Therapeutics Ltd. $85.7 Viamet Pharmaceuticals Inc. $60.0 Genomics plc...
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...Ltd. $95.0 Northwest Biotherapeutics Inc. (OTCQB:NWBO) $95.0 Mission Therapeutics Ltd. $85.7 Viamet Pharmaceuticals Inc. $60.0 Genomics plc...
BioCentury | Oct 25, 2018
Translation in Brief

Big debuts for big genomics

...interesting science until it was released to everyone else.” Peter Donnelly, University of Oxford and Genomics plc...
...data, which could drive discovery or validation of targets and biomarkers. He is CEO of Genomics plc...
...of China (see “Border Security for China’s Genomes” ). Karen Tkach Tuzman, Associate Editor BGI Genomics Co. Ltd. Genomics plc UK...
BioCentury | Aug 31, 2018
Company News

Vertex inks second deal with Genomics, leads series B

...Machine learning company Genomics plc (Oxford, U.K.) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) partnered in a target discovery...
...$186.03 on Aug. 30. Genomics plc, Oxford, U.K. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Boston, Mass. Business: Bioinformatics Allison Johnson Genomics plc Vertex...
BioCentury | Aug 30, 2018
Company News

Vertex back for second deal with Genomics, leads series B

...Machine learning company Genomics plc (Oxford, U.K.) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) partnered in a target discovery...
...and CSO David Altshuler will join Genomics' board. Vertex was up $1.17 to $186.03 Thursday. Allison Johnson Genomics plc Vertex...
BioCentury | Mar 3, 2016
Emerging Company Profile

SNP it all together

...scope of individual SNP studies limits their power of prediction for targeting the associated genes. Genomics plc...
...for over two million individuals from studies that used differing protocols. Companies and Institutions Mentioned Genomics plc...
...Lipoprotein-associated phospholipase A2 References Tkach, K. " -Omics overdrive. " BioCentury Innovations (2016) Sidebars Genomics plc...
BioCentury | Nov 9, 2015
Company News

Genomics, University of Oxford, Oxford University Hospitals NHS Foundation Trust deal

...Department of Health through its health innovation challenge fund. Genomics declined to disclose financial terms. Genomics plc...
BioCentury | Oct 19, 2015
Company News

Genomics, Biogen deal

...target immunology and neurological diseases. The companies declined to provide further details or financial terms. Genomics plc...
BioCentury | May 11, 2015
Company News

Genomics, Eisai deal

...selection and repositioning. The partners declined to comment on the deal and its financial terms. Genomics plc...
BioCentury | Feb 23, 2004
Company News

CellFactors management update

...plc , Cambridge, U.K. Business: Biomaterial/Skin/Wound Appointed: Dirk Gewert as CSO, formerly CSO of Gemini Genomics plc WIR...
Items per page:
1 - 10 of 39
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...Ltd. $95.0 Northwest Biotherapeutics Inc. (OTCQB:NWBO) $95.0 Mission Therapeutics Ltd. $85.7 Viamet Pharmaceuticals Inc. $60.0 Genomics plc...
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...Ltd. $95.0 Northwest Biotherapeutics Inc. (OTCQB:NWBO) $95.0 Mission Therapeutics Ltd. $85.7 Viamet Pharmaceuticals Inc. $60.0 Genomics plc...
BioCentury | Oct 25, 2018
Translation in Brief

Big debuts for big genomics

...interesting science until it was released to everyone else.” Peter Donnelly, University of Oxford and Genomics plc...
...data, which could drive discovery or validation of targets and biomarkers. He is CEO of Genomics plc...
...of China (see “Border Security for China’s Genomes” ). Karen Tkach Tuzman, Associate Editor BGI Genomics Co. Ltd. Genomics plc UK...
BioCentury | Aug 31, 2018
Company News

Vertex inks second deal with Genomics, leads series B

...Machine learning company Genomics plc (Oxford, U.K.) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) partnered in a target discovery...
...$186.03 on Aug. 30. Genomics plc, Oxford, U.K. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Boston, Mass. Business: Bioinformatics Allison Johnson Genomics plc Vertex...
BioCentury | Aug 30, 2018
Company News

Vertex back for second deal with Genomics, leads series B

...Machine learning company Genomics plc (Oxford, U.K.) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) partnered in a target discovery...
...and CSO David Altshuler will join Genomics' board. Vertex was up $1.17 to $186.03 Thursday. Allison Johnson Genomics plc Vertex...
BioCentury | Mar 3, 2016
Emerging Company Profile

SNP it all together

...scope of individual SNP studies limits their power of prediction for targeting the associated genes. Genomics plc...
...for over two million individuals from studies that used differing protocols. Companies and Institutions Mentioned Genomics plc...
...Lipoprotein-associated phospholipase A2 References Tkach, K. " -Omics overdrive. " BioCentury Innovations (2016) Sidebars Genomics plc...
BioCentury | Nov 9, 2015
Company News

Genomics, University of Oxford, Oxford University Hospitals NHS Foundation Trust deal

...Department of Health through its health innovation challenge fund. Genomics declined to disclose financial terms. Genomics plc...
BioCentury | Oct 19, 2015
Company News

Genomics, Biogen deal

...target immunology and neurological diseases. The companies declined to provide further details or financial terms. Genomics plc...
BioCentury | May 11, 2015
Company News

Genomics, Eisai deal

...selection and repositioning. The partners declined to comment on the deal and its financial terms. Genomics plc...
BioCentury | Feb 23, 2004
Company News

CellFactors management update

...plc , Cambridge, U.K. Business: Biomaterial/Skin/Wound Appointed: Dirk Gewert as CSO, formerly CSO of Gemini Genomics plc WIR...
Items per page:
1 - 10 of 39